A Multicenter, Randomized, Double Blind, Sham Controlled Trial to Assess the Efficacy of the Ischemic Stroke System (ISS) in Preventing Progressive Reduction of Salvageable Brain Tissue Volume in Subjects With Acute Ischemic Stroke
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 100
- 试验地点
- 4
- 主要终点
- Volume of core expansion
研究概览
简要总结
The primary objective of the study is to demonstrate that SPG (Sphenopalatine Ganglion) stimulation started within 6 hours from stroke onset slows the expansion of the infarct core volume in acute ischemic stroke.
详细描述
The goal of this study is to identify Acute Ischemic Stroke patients who have a potentially salvageable penumbra and to test if 6 hours of SPG (Sphenopalatine Ganglion) stimulation may "freeze" the volume of the penumbra and reduce the extent of tissue death.
Following a minimally-invasive implantation of the ISS injectable implant, patients will be randomized to either the Treated or Control arm in a 1:1 ratio. Randomization will be dynamic according to the patient's baseline covariates of core volume, total volume, Hypoperfusion Intensity Ratio (HIR), time to baseline imaging, age, NIHSS. Patients in the Treated arm will be treated with active SPG stimulation while patients in the Control arm will undergo sham treatment. After treatment/sham treatment, patients in both groups will undergo a follow up brain non-contrast CT, CT perfusion and CT angiography imaging, 6:45hrs±15min after baseline CTP initiation.
In the case the patient is cooperative, hand strength (pinch and grasp) evaluations should be assessed before and during the 1st treatment/ sham SPG stimulation session.
Following the assessment of the penumbra (after 6 hours) patients will be treated or sham treated for 5 additional consecutive sessions (4 hours each), the first starting within 18-24 hours from stroke onset and the others 18-26 hours from previous treatment initiation and will be followed for 90 days to assess their clinical outcome. In one session (preferably at day 2) Common Carotid Doppler examination is performed to evaluate blood flow dynamics before and during the treatment/sham session.
After the last treatment session, the implant is removed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signs & symptoms consistent with the diagnosis of large vessel occlusion in the anterior circulation
- •Age 18-90 years
- •Baseline NIHSS ≥ 10
- •Ability to initiate treatment within 6 hours from stroke onset. Stroke onset is defined as the time the patient was last seen well.
- •Large vessel total occlusion by CTA
- •Penumbra ≥ 50ml (Difference between Tmax6 volume and the ischemic core volume (CBF<38% volume)
- •Mismatch (Tmax6 volume/ischemic core volume (CBF<38% volume) ≥1.5
- •Core and HIR (Tmax10 / Tmax6) volumes:
- •HIR ≥ 0.5 or
- •0.35 ≤ HIR < 0.5 and "core volume/time from onset to imaging" ≥ 7mililiter/hour
- •Signed informed consent from patient him/herself or legally authorized representative.
排除标准
- •Unable to undergo a contrast brain perfusion scan, including an allergy to contrast media
- •Opportunity for reperfusion therapy (IV thrombolysis or endovascular treatment)
- •Neuro-imaging evidence of any intracranial hemorrhage or hemorrhagic transformation of brain infarct or other significant abnormality (e.g. tumor, abscess, suspect for subarachnoid hemorrhage, arteriovenous malformation, cerebral aneurysm).
- •Significant mass effect with midline shift.
- •Infarct core volume >150 milliliter
- •Old non-lacunar infarct in the anterior circulation on the ipsilateral hemisphere.
- •Previous stroke in the last 6 months or previous stroke with existing sequelae or with mRS > 0 for any reason
- •Pre-existing Modified Rankin Score >1, even if not stroke-related.
- •Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA/MRA (e.g., bilateral MCA occlusions, or an MCA and a basilar artery occlusion).
- •Seizures at stroke onset
- •Baseline blood glucose of <50mg/dL (2.78 mmol) or >400mg/dL (22.20 mmol)
- •Severe, sustained hypertension (Systolic BP >185 mmHg or Diastolic BP >110 mmHg)
- •Current participation in another investigational drug or device study
- •Presumed septic embolus; suspicion of bacterial endocarditis
- •Clinical signs and symptoms or evidence for a relevant lesion by neuro-imaging of an acute ischemic stroke in the posterior circulation (Vertebral, Basilar and/or Posterior Cerebral Artery territories), including but not limited to brain-stem findings and/or cerebellar findings and/or isolated homonymous hemianopia or cortical blindness.
- •Patients with bleeding propensity and/or one of the following: INR > 1.8, prolonged activated partial thromboplastin time (aPTT) ≥ 45 sec., platelets count < 75×10^9/L.
- •Serious systemic infection.
- •Women known to be pregnant or having a positive or indeterminate pregnancy test.
- •Patients with other implanted neural stimulator/ electronic devices (pacemakers).
- •History of SPG ablation ipsilateral to the stroke side.
- •Any condition in the oral cavity that prevents implantation of the INS.
- •Known sensitivity to any medications to be used during study.
- •Subjects who have a clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation. Conditions may include: cardiovascular, vascular, pulmonary, hepatic, renal or neurological (other than acute ischemic stroke), or neoplastic diseases, as determined by medical history, physical examination, laboratory tests, or ECG.
- •Subjects who, in the judgment of the investigator, are likely to be non-compliant or uncooperative during the study.
研究组 & 干预措施
Treated
Treated arm patients will be implanted and treated with one session of SPG stimulation for 6 hours and 5 additional consecutive sessions (4 hours each) of SPG stimulation, the first starting within 18-24 hours from stroke onset and the others 18-26 hours from previous treatment initiation.
干预措施: SPG stimulation (Device)
Control
Control arm patients will be implanted and receive 6 hours of sham stimulation and 5 additional consecutive sessions (4 hours each) of sham stimulation, the first starting within 18-24 hours from stroke onset and the others 18-26 hours from previous treatment initiation.
干预措施: SPG stimulation (Device)
结局指标
主要结局
Volume of core expansion
时间窗: Day 1
The primary outcome measure is the volume of core expansion (in milliliters) in 6:45h±15 min. Core expansion is the difference of two volumes: Core volume (CBF\<38%) in follow up CTP (at 6:45h±15 min) and Core volume (CBF\<38%) in baseline CTP. The difference in the mean core expansion between the Treated and Control groups will be assessed as a continuous variable with adjustment for baseline covariates (Core volume, Total volume, HIR, Time to baseline imaging). The two-sided significance level is 0.05. Handling of missing data in the primary analysis: Patients who die before the 6:45h±15 min follow-up imaging will be assigned a final core volume that equal the baseline total volume. Patients with non-interpretable follow-up imaging will be excluded from the analysis.
次要结局
- Difference in infarct volume between baseline CTP core volume and follow up NCCT infarct volume.(Day 1)
- Difference in infarct volume between baseline CTP core volume and Day-5 NCCT infarct volume(Day 5)
- 3 months mRS(Day 90±7)
- Increased blood flow in Common Carotid Doppler(Day 2-6)
- Improvement in hand motor performance(Day 1)